Clinical Trial Update: Harvoni Treatment Porphyria Cutanea Tarda [Phase 2]

View source ↗

Summary

Phase 2 clinical trial updating Harvoni treatment for Porphyria Cutanea Tarda and Hepatitis C has completed with results posted in 2023.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C
• Porphyria Cutanea Tarda

Drugs mentioned

• HARVONI (Ledipasvir and Sofosbuvir)

Snippet

Sponsor: Wake Forest University Health Sciences | Conditions: Porphyria Cutanea Tarda, Hepatitis C | Phase 2 | Status: COMPLETED | Results posted: 2023-07-03